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Abstract
Rett (RTT) syndrome is a severe neurological disorder that affects almost exclusively females. Several detectable mutations
in the X-linked methyl-CpG-binding protein 2 gene (MECP2) are responsible for the onset of the disease. MeCP2 is a key
transcription regulator involved in gene silencing via methylation-dependent remodeling of chromatin. Recent data
highlight that lipid metabolism is perturbed in brains and livers of MECP2-null male mice. In addition, altered plasma lipid
profile in RTT patients has been observed. Thus, the aim of the work is to investigate the protein network involved in
cholesterol homeostasis maintenance on freshly isolated fibroblasts and plasma from both RTT and healthy donors. To this
end, protein expression of 3-hydroxy-3methyl glutaryl Coenzyme A reductase (HMGR), sterol regulatory element binding
proteins (SREBPs), low density lipoprotein receptor (LDLr) and scavenger receptor B-1 (SRB-1) was assessed in cultured skin
fibroblasts from unaffected individuals and RTT patients. In addition, lipid profile and the abundance of proprotein
convertase subtilisin/kexin type 9 (PCSK9) were analyzed on plasma samples. The obtained results demonstrate that the
main proteins belonging to cholesterol regulatory network are altered in RTT female patients, providing the proof of
principle that cholesterol metabolism may be taken into account as a new target for the treatment of specific features of
RTT pathology.
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Introduction
Rett syndrome (RTT) is (OMIM ID: 312750) a severe
neurological disorder that affects almost exclusively females, with
a frequency of approximately 1:10,000 live births [1]. This
disorder was first recognized about 50 years ago by Andreas Rett
[2]. In 1999 mutations in the gene Methyl-CpG-binding protein 2
(MECP2) were identified as the cause of this pathology [3].
Several mutations in the X-linked MECP2 gene are detectable,
leading to wide genetical and phenotypical heterogeneity of the
disease [4]. MeCP2, a key transcriptional regulator, is critically
involved in gene silencing through methylation-dependent remod-
eling of chromatin structure [5,6]. MECP2 is able to repress gene
transcription through the association with different co-repressors
[1], even though other research studies demonstrated an opposite
effect in specific brain districts [7,8]. Approximately 80% of RTT
clinical cases show a typical clinical picture, characterized by loss
of acquired cognitive, social, and motor skills in a typical four-stage
neurological regression, together with development of autistic
behavior [4].
RTT patients appeared to develop normally up to 6–18 months
of age. Subsequently, they fall into developmental stagnation
followed by rapid deterioration, loss of previously acquired speech,
replacement of purposeful use of the hands with incessant
stereotypies, which are characteristic of the syndrome [7]. Recent
data have also demonstrated plasma lipid profile alterations in
RTT patients [9]. Notably, imbalances in both high density
lipoprotein (HDL) and low density lipoprotein (LDL) levels with
respect to aged-matched healthy donors are present [9]. The
perturbations in plasma lipid profile are accompanied by a
dramatic reduction of Scavenger Receptor B1 (SRB1). SRB1 is
ubiquitously expressed and plays pivotal roles cellular lipid uptake
[9]. Among others, it mediates the uptake of HDL-derived
cholesterol and cholesteryl ester in the liver and other tissues. Very
recently, Buchovecky and colleagues (2013) [10] showed that
cholesterol metabolism is perturbed in brains and livers of Mecp2-
null male mice, and statins (inhibitors of cholesterol biosynthesis)
ameliorate the systemic imbalance of lipid profile, alleviate motor
symptoms and confer increased longevity in Mecp2 mutant mice
[10], suggesting that cholesterol homeostasis maintenance could
be altered in patients affected by RTT. Despite this evidence, no
specific data collected on human studies are present in literature
about prospective alterations of cholesterol metabolism in RTT.
Here, we investigated the protein network of cholesterol homeo-
stasis maintenance in this rare disease. To this aim, freshly isolated
human fibroblasts and plasma derived from both RTT and
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healthy donors were used as experimental models, and the protein
levels of SRB1 [9], Sterol Regulatory Element Binding Proteins
(SREBP), 3-Hydroxy-3-MethylGlutaryl-coenzyme A Reductase
(HMGR) [11], Low Density Lipoprotein receptor (LDLr) [11,12]
were determined. Moreover, Proprotein Convertase Subtilisin/
Kexin type 9 (PCSK9) expression [13] and lipid profile were
estimated in plasma samples from RTT and healthy donors.
Materials and Methods
2.1 Subjects and ethics statements
A total of 15 female patients with classical RTT syndrome
(mean age: 20.3612.3), and 15 healthy female controls of
comparable age (mean age: 19.2614.5) participated to the study.
All the patients were consecutively admitted to the Child
Neuropsychiatry Unit of the University Hospital of Siena (Head:
J.H.). Patients were supplied with a Mediterranean diet. Olive oil
was the main fat used for seasoning and for food preparation,
whereas butter was completely devoid from the diet. In case of
dysphagia, the same foods were mashed and administered to RTT
individuals. None of the patients enrolled in this study was fed
through a feeding tube. The dietary ratio among carbohydrates,
proteins and fat was 50:20:30.
All the subjects were fasted before blood collection. Blood
samplings in the control group were carried out during routine
health, sport checks, or blood donations, while blood samplings in
patients were obtained during the periodic clinical checks. The
study was approved by the Institutional Review Board of
University Hospital, Azienda Ospedaliera Universitaria Senese
(AOUS), Siena, Italy and all informed consents were obtained in
written form from either the parents or the legal tutors of the
enrolled patients. This procedure is approved by the Institutional
Review Board of University Hospital, Azienda Ospedaliera
Universitaria Senese.
2.2 Determination of serum lipids levels
The subjects were fasted before blood sampling and plasma
lipids were measured using specific diagnostic kits following
manufacturer instructions. Serum concentration of total choles-
terol, HDL-cholesterol and triglycerides, were performed on
Cobas 6000 System (Roche Diagnostics, Italy). Total cholesterol
was analyzed by an enzymatic method based on the determination
of the D4-cholestenone following the enzymatic cleavage of
cholesterol ester by cholesterol esterase, the transformation of
cholesterol by cholesterol oxidase and the subsequent measure-
ment of the hydrogen peroxide produced by using the Trinder
reaction [14]. HDL-cholesterol was estimated with a homoge-
neous enzymatic colorimetric assay with cholesterol esterase,
cholesterol oxidase, and 4-aminoantipyrine [15]. Triglycerides
were measured by an enzymatic colorimetric method based on the
oxidation of glycerol (obtained by triglyceride hydrolysis), to
dihydroxyacetone phosphate and hydrogen peroxide. These
compounds, together with 4-aminophenazone and 4-chlorophe-
nol, form a colored product by peroxidase reaction.
2.3 Cells
Human skin fibroblasts were isolated from 3-mm skin punch
biopsy (n = 15 for RTT and n=15 for controls). Cells were
cultured in DMEM (Sigma-Aldrich, Milan, Italy), containing 20%
fetal calf serum [9] (FCS, Sigma-Aldrich) and antibiotics (100 U/
ml penicillin, 100 mg/ml streptomycin) (Lonza, Milan, Italy). Cells
were incubated at 37 Cu in a humidified atmosphere at 5% CO2
for 3 days. When fibroblasts growing from the dermal pieces
formed a confluent layer, the dermal pieces were removed and
trypsin/EDTA mixture (Sigma-Aldrich) was added to separate
fibroblasts. Cells were transferred to 25-cm2 culture flasks (Falcon,
Perugia, Italy) and subcultured in 10% FCS/DMEM. Fibroblasts
from passage 3 to 5 were used for the experiments. 16106 cells
were seeded in each flask (25 cm2), whereas the experiments were
performed when cells reached 70/80% confluence.
2.4 Lysate preparation, electrophoresis, and protein level
analysis
Cells were lysed in 80 ml lysis buffer (0.25 M Tris pH 6.8, 10%
SDS, 0.062 M NaF, and protease inhibitors) by sonication (20 sec
pulse sonication, 40% intensity). Plasma was diluted 1:20 in the
lysis buffer. Protein concentration of each sample was determined
by the method of Lowry [16]. Protein profiles were analyzed by
Western blotting following the previously used protocol [17].
Briefly, 30 mg of protein from cell lysates were resolved by 7%
SDS-PAGE at 120 V for 60 min. The proteins were subsequently
transferred electrophoretically onto nitrocellulose membrane for
90 min at 100 V. The nitrocellulose membrane was blocked at
room temperature with 5% fat-free milk in Tris-buffered saline
(138 mM NaCl, 27 mM KCl, 25 mM Tris-HCl, 0.05% Tween-
20, pH 6.8), and probed at 4uC overnight with primary antibodies
against HMGR (1:1000 code: 07-457 Upstate, Lake Placid, NY;
host: rabbit); LDLr (1:1000 code: ab30532 Abcam, Cambridge,
UK; host: rabbit); SRB1 (1:1000 code: H-180 Santa Cruz
Biotechnology, Heidelberg, Germany; host: rabbit); PCSK9
(1:1000 code: H-160 Santa Cruz Biotechnology, Heidelberg,
Germany; host: rabbit); SREBP-1 (1:1000 code: ab135133
Abcam, Cambridge, UK; host: rabbit) and SREBP-2 N-terminal
(1:1000 code: ab28481 Abcam, Cambridge, UK; host: rabbit)
which recognize the nuclear cleaved and transcriptionally active
fragment [18]. The first incubation was followed by another 1 h
incubation at room temperature with secondary anti-rabbit IgG
antibody coupled to horseradish peroxidase (1:10000 code: 170-
6515 Bio-Rad Laboratories, Milan, Italy; host: goat). The
nitrocellulose membrane was then stripped with Restore Western
Blot Stripping Buffer (Pierce Chem-ical, Rockford, IL, USA) for
10 min at room temperature and re-probed with anti-a-tubulin
(MP Biomedicals) antibody. Thus, each reported value was
derived from the ratio between arbitrary units obtained by the
protein band of interest and the respective tubulin (chosen as
housekeeping protein) or Ponceau S staining. Bound antibodies
were visualized using enhanced chemoluminescence detection (GE
Healthcare). All images derived from Western blotting were
analyzed with ImageJ (NIH, Bethesda, MD, USA) software for
Windows.
2.5 HMGR activity assay
The assay was performed by a radioisotopic method, following
the production of C14MVA (mevalonate) from 3-[14C]-HMGCoA
(specific activity 57.0 mCi/mmol. Amersham-Pharmacia, Little
Chalfont, UK). Cells were homogenized in phosphate buffer
containing 0.1 M sucrose, 0.05 M KCl, 0.04 M KH2PO4, 0.03 M
EDTA, 50 mM NaF, pH 7.4. Hundred micrograms of proteins
were incubated in presence of co-factors (20 mM glucose-6-
phosphate, 20 mM NADP sodium salt, 1 unit of glucose-6-
phosphate dehydrogenase, and 5 mM dithiothreitol). Final volume
was 180 ml. The assay was started by the addition of 10 ml (0.088 m
Ci/11.7 nmol) of 3-[14C]-HMG-CoA. The radioactivity of the
synthesized [14C]-MVA, isolated by chromatography on AG1-X8
ion exchange resin (BioRad, Italy), was measured, and the
recovery was calculated on the basis of the internal standard (3-
[3H]-MVA, specific activity 24.0 Ci/mmol. Amersham-Pharma-
cia, Little Chalfont, UK) [17].
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2.6 Statistics
Data were analyzed with unpaired Student’s t test. Values of p,
0.05 were considered statistically significant. Statistical analysis
was performed using GRAPHPAD INSTAT3 (GraphPad, La
Jolla, CA, USA) for Windows.
Results and Discussion
The aim of the presented work was to study the protein network
of cholesterol homeostasis maintenance in RTT. To this purpose,
biochemical analysis were performed on freshly isolated fibroblasts
and plasma from patients and healthy donors. The subjects
enrolled for this study were checked for plasma lipid profile.
Figure 1 demonstrates that total cholesterol and LDL-cholesterol
are significantly higher in RTT patients than in healthy controls.
This finding is in accordance with a recent published work, which
highlighted that LDL concentration is significantly elevated in
Mecp2-null mice [10]. HDL content is also shown to be increased
in RTT, further supporting other recent and published data [9].
However in this case, the difference is not statistically significant:
the discrepancy in the statistical significance could be related to a
smaller group of subjects who participated in this work if
compared with the number of persons enrolled in the study
performed by Sticozzi and colleagues [9]. On the contrary, no
variations are observable in triglycerides content. Protein level
expression of SRB1 in primary fibroblasts from RTT and healthy
donors was also checked. Western blot analysis highlights that
SRB1 expression is lower (,70%) in RTT cells than in healthy
fibroblasts (Figure 2), confirming the previously obtained results
[9].
Once ascertained the reliability of the experimental model of
fibroblast culture and the prospective deregulations both in plasma
cholesterol profile and in SRB1, the main proteins involved in the
regulatory network of cholesterol metabolism were evaluated. To
start, the attention was focused on HMGR, the rate and limiting
enzyme of cholesterol biosynthetic pathway [19,20].
HMGR activity undergoes short-term regulation operated by
phosphorylation/dephosphorylation mechanisms which respec-
tively inhibit and activate the enzyme through the activity of AMP
activated kinase and Protein Phospatase 2 A [21,22]. The
enzymatic assay was performed in presence of NaF that preserves
the in vivo phosphorylation status by permanently blocking the
activity of NaF-sensitive phosphatases [23]. The enzyme activity
results to be lower (170.565.48 pmol MVA produced/min/mg
prot) in RTT-derived fibroblasts than in healthy donors
(460.0634.06 pmol MVA produced/min/mg prot) (Figure 3),
suggesting that cholesterol synthesis is reduced in RTT fibroblasts.
The suppression in HMGR activity strongly corroborates with the
results obtained from Buchovecky and collaborators, who reported
a strong decrease in sterol synthesis in the adult brains of Mecp2
mutant mice [10]. Thus, we evaluated the amount of the
Figure 1. Plasma lipid profile in Rett and healthy donors. The
figures shows the levels of total cholesterol (T-chol), triglycerides (Try),
high density lipoproteins (HDL), and low density lipoproteins (LDL) in
Rett patients and in healthy donors. Data are the mean 6 S.D. of n = 3
independent experiments carried out on 15 subject for each
experimental group. Data were analyzed with unpaired Student’s t
test. * = p,0.05.
doi:10.1371/journal.pone.0104834.g001
Figure 2. SRB1 protein levels in Rett- and healthy donor-
derived fibroblasts. The figure shows a representative Western blot
and the densitometric analysis of SRB1 protein levels. The protein levels
were normalized with tubulin content. The data are expressed as
arbitrary units obtained analyzing the bands by using the software
ImageJ. Data are the mean 6 S.D. of n = 3 independent experiments
carried out on 15 subject for each experimental group. Data were
analyzed with unpaired Student’s t test. * = p,0.05.
doi:10.1371/journal.pone.0104834.g002
Figure 3. HMGR activity in Rett- and healthy donor-derived
fibroblasts. The figure illustrates HMGR activity performed in Rett- and
healthy donor-derived fibroblasts. The activity of the enzyme is
expressed as [14C]-mevalonate production (pmol/min/mg proteins)
from 3-[14C]-HMG CoA added to the samples. For details see the main
text. Data are the mean 6 S.D. of n = 3 independent experiments
carried out on 10 subject for each experimental group. Data were
analyzed with unpaired Student’s t test. *** = p,0.001.
doi:10.1371/journal.pone.0104834.g003
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transcription factors SREBPs, which are modulated in dependence
on the intracellular sterol content. Notably, when the amount of
sterolic compounds is low, SREBPs are proteolytically processed,
the transcriptionally active fragments are released from the
endoplasmic reticulum (ER), migrate into the nucleus and activate
the transcription of target genes involved in the regulation of lipid
metabolism (e.g. HMGR, LDLr); on the contrary, when sterols
build-up into the cell, SREBPs are retained into the ER, thus
leading to a decrease in gene transcription [24]. The amount of
the nuclear and transcriptionally active fragment of SREBP-2
(Figure 4, panel b) is increased in RTT fibroblasts (,90% fold
increase), supporting the hypothesis that alterations in cholesterol
content occurs in RTT cells. As a matter of fact, SREBP-2 is
mainly committed to the transcription of genes whose products are
involved in cholesterol metabolism [25]. Moreover, no changes are
detectable in the protein expression of SREBP-1 transcriptionally
active fragment between the two experimental groups (figure 4
panel a). As SREBP-1 is mainly committed to the transcriptional
regulation of genes involved in fatty acid and triglyceride
metabolism [25], these data corroborates with the lack of any
change in the amount of plasma triglycerides observed in RTT
patients. Thus, the present findings indicate that specific imbal-
ance in cholesterol metabolism, rather than in the homeostasis of
other lipids, are present in RTT.
The increased levels of the nuclear and transcriptionally active
fragment of SREBP-2 prompt us to hypothesize that different
Figure 4. SREBP-1, SREBP-2, HMGR, and LDLr protein levels in Rett- and healthy donor-derived fibroblasts. The figure shows a
representative Western blot and the densitometric analysis of SREBP-1 (a), SREBP-2 (b), HMGR (c), and LDLr (d) protein levels. The protein levels were
normalized with tubulin content. The data are expressed as arbitrary units obtained analyzing the bands by using the software ImageJ. Data are the
mean 6 S.D. of n = 3 independent experiments carried out on 15 subject for each experimental group. Data were analyzed with unpaired Student’s t
test. * = p,0.05 *** = p,0.001.
doi:10.1371/journal.pone.0104834.g004
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products of key target genes involved in cholesterol metabolism
could be up-regulated in RTT cells. Since cholesterol homeostasis
is guaranteed by a fragile equilibrium between biosynthesis and
uptake, HMGR and LDLr protein expression were analyzed.
LDLr is a glycoprotein receptor able to regulate plasma cholesterol
levels by removing LDL from the bloodstream [26] and, together
with HMGR, represents one of the most sensitive targets for
SREBP-2-dependent transcription [25,27,28]. As expected, both
HMGR and LDLr protein levels are increased in RTT fibroblast
if compared to healthy donor ones (,35% and ,60% respec-
tively) (figure 4 panel c and d).
Besides transcriptional events, LDLr protein levels are also
modulated by PCSK9, a 72 kDa protease highly expressed in the
liver and secreted into the systemic circulation. The binding of
PCSK9 to LDLr results in the redistribution of LDLr from the cell
membrane to lysosomes. PCSK9 seems to modify the itinerary of
LDLr, redirecting the internalized LDLr to lysosomes for
degradation and preventing its recycling to the plasma membrane
[29]. Thus, the amount of PCSK9 was checked in plasma samples
collected from RTT and healthy donors. The results demonstrated
that PCSK9 plasma levels are markedly reduced (,50%) in RTT
patients (Figure 5): the lower PCSK9 plasma content could
account, together with the increase in cellular SREBP-2 active
fraction, for the high LDLr levels found in RTT fibroblasts,
suggesting that both transcriptional and degradation pathways
could be responsible for the alteration observed in the protein
expression of this lipoprotein receptor.
Taken together, the present results suggest that the protein
network of cholesterol homeostasis maintenance is deeply altered
in RTT. Notably, the low intracellular cholesterol biosynthesis, as
a consequence of the reduced HMGR activity, induces a classical
feedback response, which determines the increase of the
transcriptionally active SREBP-2 and the consistent rise in LDLr
and HMGR protein content. In addition, the increase in LDLr is
further supported by the reduction of PCSK9 plasma levels. It is
interesting to note that LDLr overexpression in RTT fibroblasts is
not able to counteract the abnormal elevation of plasma
cholesterol content. This phenomenon could depend on several
factors, which require further investigations. For instance, defects
in LDLr membrane exposure, endocytosis and intracellular
processing,or increase of dietary cholesterol absorption from the
intestine, could represent valuable hypothesis to explain the
discrepancy between LDL receptor expression and plasma
cholesterol profile. In addition, as RTT is associated with somatic
mosaicism for MECP2 [30],the authors cannot exclude that other
organs/cells expressing wild-type MECP2could attempt to com-
pensate the reduction of HMGR activity in MECP2-mutated cells
with cholesterol and/or lipoprotein overproduction.
Even though this work highlights deep alterations in the main
proteins involved in cholesterol homeostasis maintenance, the
molecular mechanisms underlying the differences in cholesterol
metabolism between RTT patients and healthy donors are still
unknown and, to date, it is difficult to predict how cholesterol
imbalance could affect brain development and neuronal functions
in RTT individuals. Notably, the isolation of brain cholesterol
from the whole body, the presence of redundant homeostatic
mechanisms and the intercellular cholesterol shuttling in the
central nervous system [31] render more intricate the causality
linking cholesterol metabolism and RTT pathology.
A well-accepted hypothetical model for cholesterol homeostasis
in the brain suggests that during the embryonic stage, before
astrocyte differentiation, neurons are able to face their cholesterol
need by biosynthesis. Postnatally, neurons reduce or even abandon
their own synthesis and import cholesterol from astrocytes that
produce and extrude cholesterol mainly through ATP Binding
Cassette A1 (ABCA1) [31].Thus, the idea that neurons depend
constitutively on astrocyte-derived cholesterol postulates that any
interference with cholesterol delivery leads to neurological
disorders [32]. Cholesterol shuttle involves several steps that may
be perturbed in injuries or diseases. Experimental evidence
collected by Buchovecky and collaborators strengthen this
hypothesis, as modulators of cholesterol biosynthesis alleviate
motor symptoms and conferred increased longevity in Mecp2
mutant mice [10]. From these observations, we speculate that
cholesterol biosynthesis, intercellular transport and/or uptake
between neurons and astrocytes could be impaired in RTT
individuals, leading to neurodevelopmental aberration.
In conclusion, our data demonstrated that the protein network
involved in cholesterol metabolism is altered not only in Mecp2
mutant mice, but also in fibroblasts derived from RTT female
patients, thus providing the proof of principle that proteins and
enzymes belonging to the regulatory machinery of cholesterol
metabolism may be considered as new therapeutic targets for
treating specific clinical features of RTT as already demonstrated
in rodents [1,10,33].
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Figure 5. Plasma PCSK9 protein levels in Rett patients and
healthy donors. The figure shows a representative Western blot and
the densitometric analysis of PCSK9 protein levels. The samples were
normalized for protein loading by using Ponceau S staining. The data
are expressed as arbitrary units obtained analyzing the bands by using
the software ImageJ. Data are the mean 6 S.D. of n = 3 independent
experiments carried out on 15 subject for each experimental group.
Data were analyzed with unpaired Student’s t test. *** = p,0.001.
doi:10.1371/journal.pone.0104834.g005
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